US biosecurity experts are calling on industry and the Government to “get a handle” on the supply chain for drugs used in times of pandemic or bio attack.
A new formulation of Genetech’s breast cancer drug Herceptin means patients could soon receive treatment via injection, rather than time consuming intravenous drip.
Scientists at UCF (University of Central Florida) believe they have found a simpler and more efficient way to mass produce the structured nanoparticles used for drug delivery and production.
Biopharma manufacturers are putting their supply chains at risk by failing to prepare for emergencies, according to a new study by Best Practices, LLC.
Results season is well under way and in-PharmaTechnologist.com is here to bring you the latest as companies announce their chops, changes and plans for the coming quarters.
Dr. Reddy’s may not have as big a hill to climb as some observers suggest to regain customers lost as a result of the closure of its Mexican API plant, according to Barclays.
Granules India saw API sales rocket in the fiscal first quarter due – according to the firm – to an efficiency drive and the impact of rising prices in China.
Cherwell Laboratories has more than doubled the size of its Bicester, UK, plant that manufactures prepared media for microbial production after a boom in demand for its goods.
Sigma Aldrich’s fine chemicals manufacturing section SAFC ensured a modest growth for the company although its “weak” research business in the US and the EU has stunted any drastic figures, according to analysts.
Aegis Therapeutics has been granted a US patent for a novel formulation method and excipient that it claims reduces the risk of oxidative damage during MAb production and storage.
More support for IPEC Americas’ proposed excipient safety review process emerged last week with Colorcon saying it makes Pharmas more likely to use new excipients.
Hollow nano shells capable of holding both cancer fighting drugs and immune-system boosters could be the solution to oncology’s greatest delivery riddle, according to Yale University researchers.
BASF has sold its chitosan biopolymers business to Norway-based Seagarden ASA continuing the divestiture of the non-core units it acquired as part of Cognis in 2010.
The implementation of single use technology in the biopharmaceutical fill and finish process has seen a massive uptick recently because of better industry understanding, according to Pall’s Bruce Rawlings.
Scientists have uncovered a new simple way to “clean” genotoxic impurities (GTIs) in drug ingredients by mixing the solution with contamination-eating scavengers.
PPMA is fearful that the Government of Pakistan’s recent call for more foreign investment in the local pharma sector will go unheard because the industry is already overcrowded.
The upcoming tender for antiretroviral meds (ARVs) in South Africa will be opened up to more companies in a bid to tackle shortages, an insider told us.
The UK pharma manufacturing market is predicted to see a modest 2.7 per cent growth over the next five years largely due to pricing schemes set by the Government, according to a new report.
IPEC (International Pharmaceutical Excipients) Federation is calling on foreign gelatin makers to set up manufacturing plants in India in a bid to tackle an “acute” shortage of the excipient.
Ideal Cures has expanded its drug delivery tech portfolio with a new alginic acid-based, delayed-release coating that – it claims – has advantages over shellac and starch.
Royal DSM NV has confirmed that Percivia – its biosimilars joint venture (JV) with Crucell - is to cease in-house product development after failing to agree on future investment and says that job losses are likely.
The SFDA has closed down 10 gel capsule factories and revoked two licenses after finding 23 batches of products tainted with “excessive levels” of the toxic metal chromium.
The American Business Council (ABC) has warned US drugsmakers working in Pakistan to brace themselves for supply chain disruptions as the Government imposes heavy delays on the process used to allocate raw materials to manufacturers.
South Africa aims to boost its pharmaceutical production sector by developing a 70-strong list of oral solid dose drugs that it will only buy from local manufacturers.
More post-acquisition integration in the pharma excipients space this week with Ashland launching a new product line combining its own techs with coatings it bought with International Specialty Products (ISP) in 2011.